|
|
|
|
|
14.10.25 - 01:33
|
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME′s "Best Inventions of 2025" (PR Newswire)
|
|
|
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that LEQEMBI® IQLIK™, a subcutaneous......
|
|
|
14.10.25 - 01:33
|
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME′s “Best Inventions of 2025” (GlobeNewswire EN)
|
|
|
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that LEQEMBI® IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer's disease (AD) has been selected by TIME as one of the “Best Inventions of 2025” in the Medical and Healthcare category....
|
|
|
13.10.25 - 13:45
|
Biogen Aktie: Biotech-Sektor im Aufwind - Kursziel steigt (Aktiencheck)
|
|
|
New York (www.aktiencheck.de) - Biogen-Aktienanalyse von der Citigroup:
Die Analysten der Citigroup stufen die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol: IDP, NASDAQ-Symbol: BIIB) weiterhin mit "neutral" ein.
Citigroup habe im Rahmen eines Q3-Gewinnvorausblicks die Kursziele im Biotechnologie- und Pharmasektor angepasst. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
09.10.25 - 22:33
|
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome (Business Wire)
|
|
|
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal change in natural history –
– Improvements in overall clinical status at 3 years in the open-label extension studies reported by clinicians and caregivers in 95% of patients treated with zorevunersen –BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced the presentation of longer-term follow-up analyses from the ongoing open-label extension (OLE) studies of zorevunersen that support the potential of zorevunersen as a disease-modifying medicine for Dravet syndrome. These new results were presented at the 54th Child Neurology Society (CNS) Annual Meeting.
New two-year data from an analysis that was ...
|
|
|
|
|
|
|
|
|
|
|
|
|
01.10.25 - 09:06
|
AKTIONÄR-Hot-Stock BioArctic: Nächste Zulassungen (Der Aktionaer)
|
|
|
Das neuartige Alzheimer-Medikament Leqembi (Lecanemab) steht immer mehr Menschen rund um den Globus zur Verfügung. Fortan darf das Mittel auch in Australien und in einer weiteren Darreichungsform in China von der japanischen Eisai und dem US-Biotech-Konzern Biogen vertrieben werden....
|
|
|
|
|
29.09.25 - 01:33
|
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer′s Disease Approved in China (GlobeNewswire EN)
|
|
|
TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the National Medical Products Administration (NMPA) in China....
|
|
|
|
|
25.09.25 - 12:21
|
Biogen Aktie: Alzheimer-Hoffnung und Pipeline-Fantasie - Jefferies startet mit "buy"! (Aktiencheck)
|
|
|
New York (www.aktiencheck.de) - Biogen-Aktienanalyse von Jefferies & Co:
Andrew Tsai, Analyst von Jefferies & Co, stuft die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol: IDP, NASDAQ-Symbol: BIIB) in einer Ersteinschätzung mit dem Rating "buy" ein.
Jefferies sei der Ansicht, dass die Erwartungen der Investoren derzeit niedrig seien und die zentralen Risiken von Biogen allgemein bekannt seien. [mehr]...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
